Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis

Authors Alex Barnes, Dirk Hofmann, Lesley-Ann Hall, Sonja Klebe, Réme Mountifield.

Abstract

Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizumab. This was characterized endoscopically by ulcerations in the esophagus and colon. The patient was treated with high-dose intravenous glucocorticoids with good clinical response.


Keywords Ocrelizumab, inflammatory bowel disease, immunotherapy, colitis, esophagitis


Ann Gastroenterol 2021; 34 (3): 447-448

Published
2021-05-05
Issue
Volume 34, No 3 (2021)
Section
Case Report